146 related articles for article (PubMed ID: 29794918)
21. FDA approves new drug for specific type of advanced breast cancer.
Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
[No Abstract] [Full Text] [Related]
22. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
[No Abstract] [Full Text] [Related]
23. [Updated treatment of castration-resistant prostate cancer].
Xu S; Zhang ZY
Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
[TBL] [Abstract][Full Text] [Related]
24. FDA approves regorafenib (Stivarga) for GIST.
Oncology (Williston Park); 2013 Mar; 27(3):164. PubMed ID: 23687782
[No Abstract] [Full Text] [Related]
25. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
Stein CA
Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
[No Abstract] [Full Text] [Related]
26. Is it time for everolimus-based combination in castration-resistant prostate cancer?
Roviello G; Ravelli A; Barni S; Petrelli F; Bottini A; Fox SB; Generali D
Future Oncol; 2016 Aug; 12(16):1849-52. PubMed ID: 27250597
[No Abstract] [Full Text] [Related]
27. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Fujimoto N
Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
[TBL] [Abstract][Full Text] [Related]
28. FDA approves Gleevec for leukemia treatment.
FDA Consum; 2001; 35(4):6. PubMed ID: 11692893
[No Abstract] [Full Text] [Related]
29. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
30. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
31. FDA approves sorafenib for patients with inoperable liver cancer.
Lang L
Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
[No Abstract] [Full Text] [Related]
32. FDA Approves Eribulin for Advanced Liposarcoma.
Landhuis E
Cancer Discov; 2016 Mar; 6(3):OF1. PubMed ID: 26842649
[No Abstract] [Full Text] [Related]
33. FDA approves extra safe chemotherapy drug.
Expert Rev Anticancer Ther; 2002 Dec; 2(6):618-9. PubMed ID: 12503201
[No Abstract] [Full Text] [Related]
34. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
35. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
36. Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
Pal SK; Sonpavde G
BJU Int; 2015 Dec; 116(6):839-40. PubMed ID: 26542327
[No Abstract] [Full Text] [Related]
37. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
38. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
39. A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab.
Basnet A; Khullar G; Mehta R; Chittoria N
Clin Genitourin Cancer; 2017 Oct; 15(5):e881-e884. PubMed ID: 28625691
[No Abstract] [Full Text] [Related]
40. FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.
Printz C
Cancer; 2017 Jan; 123(2):191. PubMed ID: 28067949
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
